Alberta Investment Management Corp Buys 36,500 Shares of DexCom, Inc. (NASDAQ:DXCM)

Alberta Investment Management Corp raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 302,357 shares of the medical device company’s stock after buying an additional 36,500 shares during the quarter. Alberta Investment Management Corp’s holdings in DexCom were worth $23,514,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Cardinal Capital Management purchased a new position in shares of DexCom in the 4th quarter worth about $3,459,000. Kornitzer Capital Management Inc. KS lifted its stake in shares of DexCom by 45.5% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 55,752 shares of the medical device company’s stock valued at $4,336,000 after acquiring an additional 17,435 shares during the last quarter. CIBC Asset Management Inc raised its position in shares of DexCom by 1.3% in the 4th quarter. CIBC Asset Management Inc now owns 125,449 shares of the medical device company’s stock worth $9,756,000 after acquiring an additional 1,558 shares in the last quarter. Sanctuary Advisors LLC raised its position in shares of DexCom by 21.7% in the 4th quarter. Sanctuary Advisors LLC now owns 18,061 shares of the medical device company’s stock worth $1,405,000 after acquiring an additional 3,226 shares in the last quarter. Finally, Catalyst Capital Advisors LLC raised its position in shares of DexCom by 236.5% in the 4th quarter. Catalyst Capital Advisors LLC now owns 1,033 shares of the medical device company’s stock worth $80,000 after acquiring an additional 726 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

DexCom stock opened at $90.53 on Wednesday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm’s 50-day simple moving average is $82.65 and its 200 day simple moving average is $75.62. The firm has a market capitalization of $35.36 billion, a PE ratio of 63.31, a P/E/G ratio of 2.31 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities research analysts predict that DexCom, Inc. will post 1.98 EPS for the current fiscal year.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on DXCM shares. Citigroup raised their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Canaccord Genuity Group raised their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.